Movement Alert｜METIS TECHBIO-P falls 5.12% in Regular Trading, profit-taking emerged after Lilly LNP collaboration announcement

Market Focus10-20

On October 20, METIS TECHBIO-P fell 5.12% in regular trading, trading at HK$11.3, with turnover of HK$124 million.

The latest company-specific catalyst in the market was its newly announced strategic collaboration with Eli Lilly on tissue-specific lipid nanoparticle delivery solutions. Despite the initial positive reaction after the announcement, the stock later turned lower intraday, indicating increased trading divergence following the news.

Under the agreement disclosed on October 19, METIS TECHBIO-P will receive an upfront payment in the low double-digit millions of U.S. dollars and may receive up to about US$1.1 billion in development, regulatory, and commercial milestone payments, plus single-digit tiered royalties on annual net sales from resulting products. The collaboration will use its AI-driven AiLNP platform, while Lilly contributes drug discovery, development, and commercialization capabilities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment